TikoMed will be presenting IBsolvMIR in the cell and Gene Therapy section at BIO-Europe Spring

March, 13, tue,


TikoMed will be presenting IBsolvMIR at BIO-Europe in Amsterdam. IBsolvMIR is TikoMeds original project and is essentially a small molecule with protective effects from the assault from innate immune system when the cells enter the blood stream.
The drug has solid pre-clinical data and a strong safety profile.
TikoMed is now expanding its activities in the cell-therapy area and is planning for further Phase 2 studies and collaborations for various cell types and indications.